Why analysts have questions after Moderna's $1.5 billion vaccine deal

Why analysts have questions after Moderna's $1.5 billion vaccine deal
Hollis Johnson/Business Insider

Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider's healthcare editor Lydia Ramsey Pflanzer and the healthcare team. Subscribe here to get this newsletter in your inbox every weekday.



It's Lydia Ramsey Pflanzer here, back on newsletter duty after a refreshing week off. Hope you've been enjoying dispatches from my colleagues here on the healthcare team!

Let's get into today's healthcare news, including why one Wall Street analyst is becoming bullish on Moderna, the 21 biotech startups top VCs are betting will take off, and why the World Health Organization thinks you should postpone your routine dentist's appointment.


A $1.5 billion deal for Moderna's coronavirus vaccine has top analysts like JPMorgan questioning how lucrative the shot will be

Read the full story from Andrew Dunn here>>

Meet the 21 biotech startups that top VCs say are poised to take off in the next 12 months

Read the full story from Andrew Dunn and me here>>

WHO: Postpone your dental check-ups and cleanings unless you have an emergency

Read the full story from Julia Naftulin here>>


More stories we're reading:

I'll be back tomorrow with your weekly recap of healthcare news and maybe some photos from my week away from a computer screen.

Until then, you can find me at lramsey@businessinsider.com, and you can reach the whole team at healthcare@businessinsider.com.

Don't forget to subscribe to this newsletter here if you haven't already!

- Lydia